Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Stroke. 2018 Sep;49(9):2200–2210. doi: 10.1161/STROKEAHA.118.021179

Figure 4.

Figure 4

EUK-134 treatment decreased ROS level and reduced ischemic brain injury at 6 and 24h after reperfusion, but cytosolic labile zinc accumulation was reduced only at later reperfusion time. EUK-134 was injected subcutaneously 30min before MCAO as well as 3 and 8h after reperfusion. (A) Effect of EUK-134 on ROS formation as indicated by H2DCF-DA-stained cells. (B) Effect of EUK-134 on zinc accumulation as indicated by NG-stained cells. Bars=20μm. (C) Effect of EUK-134 on cerebral infarction volume, calculated by TTC-stained coronal sections. (D) Effect of EUK-134 on neurological assessment and motor function, assessed by neurological deficit scores and foot-fault-placing test. Data are means±SD (n=5 for A&B; n=8 for C&D). *P<0.05 vs vehicle-treated MCAO group.